Ibex Wealth Advisors raised its holdings in Merck & Co., Inc. (NYSE:MRK – Free Report) by 59.7% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 165,708 shares of the company’s stock after acquiring an additional 61,957 shares during the period. Merck & Co., Inc. makes up 1.7% of Ibex Wealth Advisors’ investment portfolio, making the stock its 12th largest position. Ibex Wealth Advisors’ holdings in Merck & Co., Inc. were worth $24,079,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also bought and sold shares of MRK. Fisher Asset Management LLC increased its holdings in shares of Merck & Co., Inc. by 8.3% in the 3rd quarter. Fisher Asset Management LLC now owns 41,699,432 shares of the company’s stock worth $6,059,345,000 after buying an additional 3,183,169 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Merck & Co., Inc. by 23.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 15,456,039 shares of the company’s stock worth $1,858,938,000 after acquiring an additional 2,969,856 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of Merck & Co., Inc. by 10.5% during the 1st quarter. Bank of America Corp DE now owns 30,774,221 shares of the company’s stock worth $3,701,831,000 after acquiring an additional 2,919,780 shares during the last quarter. Assenagon Asset Management S.A. grew its position in Merck & Co., Inc. by 263.7% in the second quarter. Assenagon Asset Management S.A. now owns 2,702,992 shares of the company’s stock worth $347,334,000 after acquiring an additional 1,959,778 shares in the last quarter. Finally, Wellington Management Group LLP increased its stake in Merck & Co., Inc. by 2.3% in the second quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company’s stock valued at $11,083,033,000 after acquiring an additional 1,934,312 shares during the last quarter. 76.07% of the stock is owned by hedge funds and other institutional investors.
Merck & Co., Inc. News Roundup
These are some of the MRK news items that stood out recently:
- Positive Sentiment: The EMA’s CHMP recommended expanding ENFLONSIA’s use to help prevent severe RSV lower respiratory tract disease in vulnerable children up to 24 months old, including through their second RSV season. The broader eligible population could support the medicine’s commercial opportunity in Europe. Merck ENFLONSIA CHMP recommendation
- Positive Sentiment: The CHMP also recommended WELIREG plus lenvatinib for adults with advanced clear-cell renal cell carcinoma after anti-PD-1/PD-L1 treatment. This would extend WELIREG into another treatment setting and expand Merck’s oncology portfolio in Europe. Merck WELIREG CHMP recommendation
- Neutral Sentiment: Both decisions are CHMP recommendations; European Commission approval is still needed. Any financial contribution will also depend on launch timing, uptake and competition.
Analyst Ratings Changes
MRK has been the topic of a number of research analyst reports. BMO Capital Markets increased their target price on Merck & Co., Inc. from $142.00 to $170.00 and gave the company an “outperform” rating in a research note on Thursday, August 20th. Jefferies Financial Group raised their price objective on Merck & Co., Inc. from $152.00 to $175.00 and gave the company a “buy” rating in a report on Thursday, August 20th. Freedom Broker lifted their price target on shares of Merck & Co., Inc. from $125.00 to $140.00 and gave the stock a “hold” rating in a research note on Monday, November 2nd. Daiwa Securities Group raised shares of Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 price target on the stock in a research note on Wednesday, August 12th. Finally, Citigroup upped their price target on shares of Merck & Co., Inc. from $125.00 to $145.00 and gave the company a “neutral” rating in a research report on Monday, October 12th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $155.74.
Get Our Latest Stock Analysis on Merck & Co., Inc.
Merck & Co., Inc. Stock Down 0.0%
Shares of NYSE:MRK opened at $147.74 on Monday. Merck & Co., Inc. has a 1 year low of $91.49 and a 1 year high of $156.92. The company has a market cap of $364.21 billion, a PE ratio of 152.31, a P/E/G ratio of 6.77 and a beta of 0.13. The company has a debt-to-equity ratio of 1.11, a current ratio of 1.35 and a quick ratio of 1.14. The stock’s 50-day moving average is $146.16 and its 200 day moving average is $128.61.
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The company reported $2.49 EPS for the quarter, beating analysts’ consensus estimates of $2.09 by $0.40. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 3.64%. The business had revenue of $18.09 billion during the quarter, compared to analyst estimates of $17.33 billion. During the same quarter in the prior year, the company posted $2.58 EPS. Merck & Co., Inc.’s quarterly revenue was up 4.7% compared to the same quarter last year. Sell-side analysts anticipate that Merck & Co., Inc. will post 2.82 EPS for the current year.
About Merck & Co., Inc.
Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company’s research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.
Featured Articles
- Five stocks we like better than Merck & Co., Inc.
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
